Article ID Journal Published Year Pages File Type
4000125 Urologic Oncology: Seminars and Original Investigations 2013 5 Pages PDF
Abstract

ObjectivesThe role of robot assisted radical prostatectomy (RARP) for high-risk prostate cancer (CaP) is controversial, as is the role of RARP in elderly men. We evaluate outcomes of elderly patients with high-risk CaP who have chosen RARP over radiation or hormonal therapy.Materials and methodsBetween April 2001 and November 2009, 69 elderly patients (≥70 years) with high-risk CaP underwent RARP at our institution. High-risk CaP was defined using the D'Amico criterion, PSA ≥ 20 ng/ml, biopsy Gleason score 8–10, or clinical stage ≥ cT2C. Outcomes were retrospectively analyzed.ResultsPreoperative high-risk features were PSA > 20: 11 patients (15.9%), biopsy Gleason score 8–10: 43 (62.3%), or clinical stage ≥ cT2C: 25 (36.2%). Median OR time was 175 minutes (IQR: 136.8–202.5) and median EBL was 150 cc (IQR: 100–200). There were 4 complications (5.8%): urine leak (2) and ileus (2). Median duration of stay was 1 day and no patient had a hospital stay over 3 days. On final pathology, 26 men (37.7%) had organ-confined disease with negative surgical margins and 27 (39.1%) had extracapsular extension with negative margins. Biochemical recurrence occurred in 12 patients (17.4%) at a median follow-up of 37.7 months. There was a single incidence of positive lymph nodes at the time of surgery (1.4%). Actuarial biochemical recurrence-free survival was 91% at 12 months and 86% at 36 months. Functional outcomes assessed by patient administered questionnaire at a median follow-up of 26.2 months showed an improvement in median IPSS score from 8.0 preoperatively to 5.0 postoperatively (P = 0.0004) with 53 (81.5%) of patients using 1 pad per day or less for urine control and 7 patients (33.3%) of the 21 men with preoperative SHIM score > 21 preoperatively achieving erections sufficient for intercourse.ConclusionsRobotic RP is safe and feasible in select elderly patients with high-risk CaP with good intermediate oncologic and functional outcomes. Advanced chronological age should not be an absolute contraindication for RARP in these patients.

Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
, , , , , ,